Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Berry Genomics Partner on Targeted NGS Assays in China

NEW YORK – Twist Bioscience and China's Berry Genomics on Monday announced a partnership on next-generation sequencing target enrichment and library preparation tools.

Under their agreement, the firms will work together to develop new research and in vitro diagnostic NGS panels for inherited diseases.

Berry Genomics will also offer Twist's NGS panels for cancer diagnosis.

Financial and other details of the deal were not disclosed.

South San Francisco, California-based Twist offers NGS-based genotyping assays using its synthetic oligonucleotides to capture target sequences. NGS products became the company's top revenue generator in the company's first quarter of fiscal year 2021, which ended Dec. 31, 2020.

Last year, Berry Genomics partnered with cancer genomics firm Personalis to facilitate the latter company's expansion into China. Berry also has a partnership on clinical sequencing with Illumina.

The Scan

Polarized Science Confidence

A new survey finds that confidence in science among US adults is increasingly polarized, the Associated Press says.

Time to Sit Back and Relax

NPR reports that the US National Institutes of Health has transferred the last of its eligible former research chimpanzees to a sanctuary.

Omicron-Focused Vaccines

The New York Times reports both Pfizer-BioNTech and Moderna have launched trials of SARS-CoV-2 vaccines targeting the Omicron variant.

Nature Papers Present Cloud-Computing Analysis Approach, Transcription Factor With Role in Bacterial Genome Organization

In Nature this week: researchers describe the free, open-source cloud-computing infrastructure Serratus and more.